Rafferty Asset Management
KRON

Rafferty Asset Management’s Kronos Bio KRON Stock Holding History

Rafferty Asset Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-107,021
Closed -$774K – 1180
2022
Q1 		$774K Buy
107,021
+30,553
+40% +$261K ﹤0.01% 834
2021
Q4 		$1.04M Buy
+76,468
New +$1.2M 0.01% 845

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Rafferty Asset Management's KRON Position: Q2 2022 in Review

Rafferty Asset Management sold out of Kronos Bio (KRON) in Q2 2022, closing a stake of 107,021 shares — an estimated $774K sold.

Rafferty Asset Management first reported a position in KRON in Q4 2021 and held it in 2 quarters. The position peaked at $1.04M in Q4 2021. 93 funds tracked by Wall St. Rank hold KRON as of Q2 2022.

  • Rafferty Asset Management reported no remaining Kronos Bio position as of Q2 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 107,021 Kronos Bio shares in Q2 2022, an estimated $774K.
  • Rafferty Asset Management first reported a position in Kronos Bio in Q4 2021 and held it in 2 quarters.
  • Rafferty Asset Management's Kronos Bio position peaked at $1.04M in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2022.

Based on Rafferty Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.